Literature DB >> 10520855

Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?

Z Ben-Ari1, E Osman, R A Hutton, A K Burroughs.   

Abstract

OBJECTIVE: Cirrhosis is commonly associated with haemostatic dysfunction. The similarities of laboratory tests of disseminated intravascular coagulation (DIC) to those found in cirrhosis has led to the belief that DIC is a feature of the haemostatic failure of cirrhosis.
METHODS: The aim of this study was to determine whether DIC is part of the coagulopathy of cirrhosis by applying quantitative tests for prothrombin fragment 1 + 2, antithrombin III, thrombin-antithrombin complex, and specific fribrinogen degradation products levels (XDP), as well as the thrombelastograph for detecting the Clot Lysis Index.
RESULTS: Fifty-two stable cirrhotic patients (33 men, 19 women; mean age, 58.8 yr; range, 24-72 yr) with differing etiologies were studied. On tests of thrombin generation: thrombin-antithrombin complexes, fibrin(ogen) degradation products, and prothrombin fragments 1 + 2 were not found to be significantly different from an age- and gender-matched control group (p = 0.18, 0.3, and 0.67, respectively), whereas albumin, Factor V, fibrinogen, antithrombin III, and alpha2-antiplasmin were all significantly low (p = 0.0004, 0.002, 0.06, 0.004, and 0.004, respectively), reflecting reduced synthetic function and correlation in ascitic and non-ascitic patients. There was no correlation between impaired synthesis (antithrombin III and alpha2-antiplasmin) and indices of DIC (prothrombin fragment 1 + 2, thrombin-antithrombin complexes, and XDP) (p = not significant). The percentage of patients with high prothrombin fragments 1 + 2 and thrombin antithrombin levels in each Child grade group was similar. Thrombin time was significantly elevated in the cirrhotic group (a manifestation of low fibrinogen levels). The Clot Lysis Index as measured by thrombelastography was significantly abnormal, indicating mild hyperfibrinolysis.
CONCLUSION: We conclude that DIC is not part of the coagulopathy in stable liver cirrhosis without recent complications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520855     DOI: 10.1111/j.1572-0241.1999.01446.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

Review 1.  Infection, coagulation, and variceal bleeding in cirrhosis.

Authors:  U Thalheimer; C K Triantos; D N Samonakis; D Patch; A K Burroughs
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 2.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 3.  Portal vein thrombosis in liver cirrhosis.

Authors:  Nao Kinjo; Hirofumi Kawanaka; Tomohiko Akahoshi; Yoshihiro Matsumoto; Masahiro Kamori; Yoshihiro Nagao; Naotaka Hashimoto; Hideo Uehara; Morimasa Tomikawa; Ken Shirabe; Yoshihiko Maehara
Journal:  World J Hepatol       Date:  2014-02-27

Review 4.  Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system.

Authors:  Masayuki Ishii; Toru Mizuguchi; Kohei Harada; Shigenori Ota; Makoto Meguro; Tomomi Ueki; Toshihiko Nishidate; Kenji Okita; Koichi Hirata
Journal:  World J Hepatol       Date:  2014-10-27

Review 5.  Coagulopathy in liver disease: Lack of an assessment tool.

Authors:  Annabel Blasi
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

6.  Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis.

Authors:  Sasa-Marcel Maksan; Eduard Ryschich; Zilfi Ulger; Martha Maria Gebhard; Jan Schmidt
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

7.  Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: an in vivo analysis.

Authors:  Sasa-Marcel Maksan; Zilfi Ulger; Martha Maria Gebhard; Jan Schmidt
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

8.  Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics.

Authors:  Libang Yang; Kyle D Rudser; LeeAnn Higgins; Hugo R Rosen; Atif Zaman; Christopher L Corless; Larry David; Glenn R Gourley
Journal:  Dig Dis Sci       Date:  2011-05-17       Impact factor: 3.199

9.  Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis.

Authors:  Jung Wha Chung; Gi Hyun Kim; Jong Ho Lee; Kyeong Sam Ok; Eun Sun Jang; Sook-Hyang Jeong; Jin-Wook Kim
Journal:  Clin Mol Hepatol       Date:  2014-12-24

10.  Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

Authors:  Valeria Rossetto; Luca Spiezia; Marco Senzolo; Krissia Isabel Rodriguez-Castro; Sabrina Gavasso; Barry Woodhams; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2013-03-17       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.